Whenever mentally incapacitated lowlifes like you show up in full force on the message board, it's a signal the stock is about to take. To our benefit, you're too stupid to know you're a perfect contrary indicator for the stock movement.
"When that day comes I'll close my position and take my proceeds and open a long position."
Not if you wake up one morning and it's gapped up 50%. Given how undervalued the stock is coupled by a pending SPA/P3 and who knows whatever is in the works with it, that's not a farfetched scenario.
Like I said, professional smart money shorts have been covering sensing what is in the works, while dumb money retail shorts have not. Congratulations, you're the poster child for a dumb money retail short
Thanks Batermere. Why would this guy out of the blue attack me for no reason...unless it's because he's getting very nervous that my expectation that we could see some material developments with ADXS in the next couple months will turn out to be true.
Carry on with your short and distort lies. What's funny is you're probably short 1000 shares and that's most of your net worth so you're desperate to support your investment position through ignorant attempts at scaring others. Well, professional shorts have been covering because they know ADXS is severely undervalued and setting up for some big developments in the coming weeks and months (ASCO GOG P2 data update, high dose update, start of P3 and SPA and the big wildcard a BP partnership to kick off P3?). But keep on shorting. You should go all in and bet the farm and increase your short to 1500 shares.
Well by definition Dan is looking to partner with the combo therapy trials. In my mind, the big question is can he negotiate a significant monotherapy deal similar to Aduro/JNJ with either HPV/cervical cancer, HER2 or Neo. I wouldn't be surprised to see an HPV deal going into P3. We already have the regional deals lined up, but nothing on the core US and Europe. I would think Dan would want to lock in a commercialization deal for the core markets when P3 starts.
Good points. I'm holding tight as well, as it does appear a lot is setting up. If we don't see a big BP deal this year at some point I'd be surprised and disappointed.
Ignatius, I thought they bought the maximum ADXS allowed, which is around 20%, so they would have bought roughly the same proportion each capital raise. A few month ago, I went through each capital raise and the dollar amount and arrive at approximately a $12 weighted average price for all the dilutions Dan has done, so in aggregate investors that have come to the company under Dan's watch are very much underwater. IMO what adds insult to injury is the excessive shareholder assets Dan took for himself, which in itself and the way Dan got them has contributed at least in part to the low share price and value of the shares today. If I were Adage with the large stake it has, if nothing changes this year I would consider taking an activist stance for change/replacement of the CEO. I bet from Adage's perspective that's preferable to liquidating their position, which would be difficult to do without pushing it down that much further than even where we are today.
Seriously man, why on earth would you short a stock as undervalued as ADXS? Have you even bothered to look at the pipeline, clinical data to date and collaborations in place that could turn into material deals in the coming months?
Darkerhorse, I think your theory is the most likely explanation for the delay. I hope they release the data around the same time as the partnership announcement (with Pfizer).
Hd, that's why I'm not selling a share now. We have two BP collaborations that could turn into a big deal or more than one deal. I could see something happening on HPV monotherapy or HER2 or Neo potentially very soon before a combo deal given we are waiting on combo data later this year.
Not sure this following was necessary to include in the PR. Always all about "Dan" but shareholders are more interested in the value of their investment. Disconnect between Dan's self-interest and the interests of the company's owners.
"Daniel O’Connor has 20 years of executive, legal, and regulatory experience in the biopharmaceutical industry, including senior leadership positions at ImClone Systems and PharmaNet, now known as Inventiv Health. In 2015, Ernst & Young named Mr. O’Connor Entrepreneur of the Year® in New Jersey. He serves as an advisor to the Dean of the Penn State University’s Dickinson School of Law and is a member of the Board of Trustees of BioNJ."
I've seen some posts trying to understand why ADXS is still under a $300 million market cap when we're about to enter Phase 3, have Phase 2 cervical cancer data that have shown efficacy better than any past trial on the indication and just received fast track for human osteosarcoma coupled with stellar canine trial results. IMO the reason is "management". We're all still here because of the promise of the platform despite poor management. At what point do our large shareholders say enough is enough, we need a new CEO to drive shareholder value.
The current stock value shows shareholders were right in opposing Dan's efforts to take an unprecedented amount of shareholder assets for himself without being accountable to performance and instead advocated alignment of interests in which management would only get paid excessive "incentive" compensation (options) if shareholders shared in the reward. Fast forward three years, Dan got his reward but has yet to deliver the $50 share price he pitched to shareholders would happen in two years. I sense Dan may have a future in politics...
Ufortunately, we learned the hard way why Dan was so insistent of taking RSUs instead of options - options would have held him accountable to creating shareholder value since the options would only have value if the stock price rose, but with RSUs Dan recognized that he would be paid handsomely regardless of whether he created shareholder value. He was right - he hasn't created shareholder value but has gotten an unprecedented number of RSU grants which are immediately in the money irrespective of value creation.
Do you think the woman who was able to play the piano again after taking AVXL treatment was being scammed as well?